About the condition

Types of Neuroendocrine tumours (NETs)

  • Gastrointestinal - Gastric, duodenal, pancreatic, small intestine, appendiceal, colon, rectum, ovary, unknown primary.
  • Thorax – lung
  • Neck/Thorax - Thyroid, parathyroid, thymus
  • Pancreas – Non-functioning. Functioning (gastrinoma, Vasoactive Intestinal Peptide [VIP]-oma, insulinoma, somatostatinoma glucagonoma).
  • Multiple endocrine neoplasia (MEN) -
  • MEN1 - Parathyroid, anterior pituitary, enteropancreatic endocrine cells.
  • MEN2A - Medullary thyroid, phaeochromocytoma, primary parathyroid hyperplasia.
  • MEN2B - Medullary thyroid, phaeochromocytoma, mucosal neuromas, intestinal ganglioneuromas and marfanoid habitus and other skeletal abnormalities.
  • Adrenal - Phaeochromocytoma.
  • Extra-adrenal - Paraganglioma.
  • Goblet cell – Appendix
  • Other - Merkel cell skin cancer, pituitary neuroendocrine tumours.

Neuroendocrine tumours arising within the digestive system are classified as well-differentiated [slower growing] (traditionally referred to as carcinoid tumours when they arose in the tubular gastrointestinal tract and pancreatic neuroendocrine [islet cell] tumours when they arose in the pancreas or, in the case of gastrinomas, in the proximal portion of the duodenum), or poorly differentiated neuroendocrine carcinomas [fast growing] which are generally high grade and can resemble small cell or large cell neuroendocrine carcinoma of the lung.

Table 4: Nomenclature and classification for digestive system neuroendocrine tumours

Pulmonary carcinoids as a whole are well differentiated as opposed to small cell lung carcinoma and large cell neuroendocrine carcinoma, with typical carcinoids sharing some similarities to Grade 1 NETs and atypical carcinoids showing some similarities to Grade 2 NETs of the gastroenteropancreatic tract.

Typical carcinoid has fewer than 2 mitoses/2mm2 and absence of necrosis, and atypical carcinoid has 2-10 mitoses/2mm2 and/or foci of punctate necrosis.  Small cell lung carcinoma and large cell neuroendocrine carcinoma have more than 10 mitoses/2 mm2 and extensive necrosis.

Last updated: August 2019

Christie stories during the COVID-19 pandemic

During the COVID-19 pandemic, we're doing all we can to make sure patients get the treatment, information and support they need. Read some stories from our patients and staff to find out what The Christie is doing at this difficult time.

View All
Corinne Faivre Finn
“We have seen a lot of our research staff return to the office. This has massively improved morale as it is a lot easier to connect with people.”
Corinne Faivre-Finn, Christie consultant
Read More
Read More
profile placeholder image
“The experience has allowed me to be able to hear what is not being said. The extraordinary strength and resilience of individuals as they greet you with a smile… when you are aware of the pain and anguish they will be going through.”
Digital services team, redeployed to telephone patients
Read More
Read More
“Of course, the COVID-19 virus has not gone away – we have to be cautious and we have to proceed in an appropriate way.”
Professor John Radford, director of research at The Christie
Read More
Read More